Compugen Ltd.
72 Pinchas Rosen Street
Tel Aviv,
69512
Israel - Map
Phone: 972 3 765 8585
Fax: 972 3 765 8555
Web Site: http://www.cgen.com
| Compugen Ltd., an early stage drug and diagnostic discovery company, offers therapeutic and diagnostic biomarker product candidates for cancer, cardiovascular, and immune-related diseases in North America and Israel. It develops products using computer-based discovery platforms, as well as through analyzing DNA or RNA sequences, gene expression data, protein network data, data related to drugs in development, and drugs already being commercialized. The companys validated discovery platforms include Splice Variant based Therapeutic Proteins, Nucleic-Acid Disease Markers, Protein Disease Markers, Monoclonal Antibody Targets, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, GPCR Therapeutic Peptide Ligands, New Indications, Disease-Associated Conformation Blockers, and Viral Peptides Discovery. Its therapeutic product candidates include CGEN-241, a splice variant of the MET receptor; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, the MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; CGEN-25008, a peptide antagonist of the Clusterin protein; CGEN-25009-4, an agonist peptide of the LGR7 receptor; CGEN-54, a splice variant of the MCP-1; CGEN-34, a splice variant of the peptide ANP; and CGEN-50001, a small molecule drug. The companys diagnostic products include CGEN-144, a variant of the Troponin I biomarker; CGEN-438, a blood based biomarker for lung cancer; CGEN-6, a secreted splice variant protein; and CGEN-327, a biomarker for ovarian cancer. It also develops plant traits to the agbio industry through the use of a platform combining computational genomics, molecular biology, and breeding methods. Compugen has collaboration and license agreements with Roche; Siemens Healthcare Diagnostics, Inc.; Ortho-Clinical Diagnostics; Biosite; Teva Pharmacuetical Industries; Merck & Co.; Medarex, Inc.; and Bayer Schering Pharma AG. The company was founded in 1993 and is based in Tel Aviv, Israel. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Martin Gerstel , 67
Co-Chief Exec. Officer, Pres |
N/A
| N/A | Dr. Anat Cohen-Dayag Ph.D., 42
VP of R&D |
N/A
| N/A | Ms. Dikla Czaczkes Axselbard , 35
Chief Financial Officer |
N/A
| N/A | Mr. Eran Aharonson ,
VP of Computational Life Science R&D and Member of Sr. Management Team |
N/A
| N/A | Mr. Erez Chimovits , 45
Exec. VP of Commercial Operations and Pres of Compugen USA, Inc |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
0.05 (1.77%) 
Profile
